1167 and 77V Related Headlines
Go Back- Jacobio Announces 2025 Annual Results
- Jacobio Pharma licenses cancer drug to AstraZeneca for $2 billion
- Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
- Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference
- Jacobio Pharma sells 80% stake in cardiovascular unit for RMB 200 million
- Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
- Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
- Jacobio Pharma Announces 2025 Interim Results
1167 and 77V Related Press Releases
Go Back- Jacobio Announces 2025 Annual Results
- Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
- Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference
- Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
- Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
- Jacobio Pharma Announces 2025 Interim Results
